2024 Intercept pharmaceuticals inc - By: Alfasigma S.p.A. via Business Wire. November 08, 2023 at 09:12 AM EST. Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of …

 
MORRISTOWN, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company .... Intercept pharmaceuticals inc

Mar 2, 2022 · NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2021. MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Subject: Intercept Pharmaceuticals, Inc. – Tender Offer Option Symbol: ICPT Date: 11/07/2023 Intercept Pharmaceuticals, Inc. (ICPT) is the subject of an Offer to Purchase (The “Offer”), as described below: Purchaser:Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma S.p.A.MORRISTOWN, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2022.THIS EMPLOYMENT AGREEMENT (the “Agreement”), made effective as of 2 June, 2021, is entered into by Intercept Pharmaceuticals, Inc. (the “Company”) and M. Michelle Berrey (“Executive”). WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company.Mar 2, 2022 · NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2021. ১২ সেপ, ২০১৪ ... Professor Pellicciari was the co-founder and remains Head of Medicinal Chemistry at Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (“Intercept ...Intercept Pharmaceuticals, Inc. --Alfasigma S.p.A. and Intercept Pharmaceuticals, Inc. announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned ...Intercept Pharmaceuticals Inc.: Intercept is a biopharmaceutical company that manufactures drugs to treat non-viral liver disease. BioNTech SE: ...Intercept Pharmaceuticals, Inc.ICPT announced that the FDA has accepted the company’s new drug application (NDA) for obeticholic acid (OCA) that seeks accelerated approval for the treatment of ...Intercept Pharmaceuticals, Inc. December 23, 2022 at 7:50 AM · 4 min read NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 ...Jun 23, 2023 · FDA issued a Complete Response Letter to Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) marketing application seeking approval for obeticholic acid (OCA) for pre-cirrhotic fibrosis due to NASH ... A vertical intercept is a point where a line crosses the vertical axis, or y-axis, on the Cartesian coordinate plane. When evaluating a function, the vertical intercept can be found by setting the input, or x value, to zero.Jan 4, 2023 · MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023. When it comes to staying informed and up-to-date with the latest news, there are countless options available. One popular choice for many people is Apple News, a news aggregator developed by Apple Inc.Nov 8, 2023 · BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ... What is PBC? Primary Biliary Cholangitis (PBC) is a progressive autoimmune disease that damages the bile ducts in the liver. PBC is a leading cause of liver transplant for women. Learn more Ally, living with PBC Patient Resources We are committed to helping patients access disease education, treatment support and financial options. Read more BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s ...Inside Intercept Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Expense Highlight. Net cash used in operating activities of $198.2 million for continuing operations during the year ended December 31, 2020 was primarily a result of our $273.4 million net loss from continuing operations and a net decrease in operating assets and …Sep 26, 2023 · Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”). Intercept Pharmaceuticals, Inc. manufactures and markets biopharmaceutical products. The Company focuses on the development and commercialization of therapeutics to …Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases.BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s ...May 19, 2023 · MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs ... Intercept Pharmaceuticals, Inc.ICPT announced that the FDA has accepted the company’s new drug application (NDA) for obeticholic acid (OCA) that seeks accelerated approval for the treatment of ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.Hou Liu v. Intercept Pharmaceuticals, Inc., 2020 WL 1489831, at *3 (S.D.N.Y. Mar. 26, 2020). “Intercept urged healthcare providers to ensure that patients with late-stage PBC received the correct drug dose and to monitor all Ocaliva patients for liver-related adverse reactions.” Id.Shares of Intercept Pharmaceuticals, Inc. ICPT gained 12.4% in the last six months compared with the industry’s growth of 0.3%. Investors are upbeat on the performance of lead drug Ocaliva and ...Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Glenn Dobbs, Zeke Bratkowski, Tommy Wade, Ken Stabler, Steve DeBerg and Ty Detmer are tied for the NFL record for the most interceptions thrown in one game. Each quarterback has thrown seven interceptions in a single Sunday contest.NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the …MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Jun 22, 2023 · MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter ... Shares of Intercept Pharmaceuticals Inc fell about 16% on Monday over concerns about the prospects of the company's drug to treat a type of fatty liver disease after the regulator's advisory panel ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Save hours of research time and resources with our up-to-date Intercept Pharmaceuticals Inc Strategy Report; Understand Intercept Pharmaceuticals Inc position in the market, performance and strategic initiatives. Gain competitive edge and increase your chances of …Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist ... Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Agreement and Plan of Merger, dated September 26, 2023, among Intercept Pharmaceuticals, Inc., Alfasigma S.p.A. and Interstellar Acquisition Inc.* 99.1 Press Release of Intercept Pharmaceuticals, Inc., dated September 26, 2023 104 Cover Page Interactive Data File (embedded as Inline XBRL document)To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ...Nov 8, 2023 · BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ... Intercept Pharmaceuticals Inc.: Intercept is a biopharmaceutical company that manufactures drugs to treat non-viral liver disease. BioNTech SE: ...The information agent for the tender offer is Georgeson LLC. Intercept stockholders who need additional copies of the Offer to Purchase, Letter of Transmittal or related materials or who have ...MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed.Intercept Pharmaceuticals, Inc. --Alfasigma S.p.A. and Intercept Pharmaceuticals, Inc. announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned ...Alfasigma (ALFA) and Intercept Pharmaceuticals (ICPT) announced the completion of Alfasigma's acquisition of Intercept. The deal adds Ocaliva, an FDA-approved treatment for primary biliary cholangitis, to Alfasigma's portfolio, strengthening its presence in the US market. The acquisition also enhances Alfasigma's innovation and R&D …FXR is a nuclear receptor found in the liver, intestine, kidney, and adipose tissue. FXR regulates many biological processes, including: Bile acid metabolism. Inflammation. Fibrosis. Glucose metabolism. Lipid metabolism. In addition to their role in digestion and absorption, bile acids have been shown to bind and activate dedicated receptors ... Jan 4, 2023 · MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023. Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting.Jan 20, 2023 · Intercept Pharmaceuticals, Inc.ICPT announced that the FDA has accepted the company’s new drug application (NDA) for obeticholic acid (OCA) that seeks accelerated approval for the treatment of ... MORRISTOWN, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to sell to Advanz Pharma, a …Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. The biopharmaceutical company had revenue of $88.79 million for the quarter, compared to the consensus estimate of $88. ...Alfasigma S.p.A. today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation, has commenced a cash tender offer to purchase all of the outstanding ...Director. Keith Gottesdiener, M.D. has served as a member of our Board of Directors since July 2016. Since July 2020, Dr. Gottesdiener has served as the President and Chief Executive Officer and as a director of Prime Medicine, Inc., a biopharmaceutical company based in Cambridge, Massachusetts. Prior to that, from October 2011 until March 2020 ... BOLOGNA, Italy, October 11, 2023--Alfasigma S.p.A. ("Alfasigma") today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation ("Purchaser"), has ...MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Alfasigma S.p.A. today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation, has commenced a cash tender offer to purchase all of the outstanding ...Intercept recognized $68.0 million in net sales in the first quarter 2023 compared to $59.2 million in net sales in the prior year quarter. In the quarter ended March 31, 2023, Intercept recorded ...Hayward Pool Products Inc. is a leading manufacturer and distributor of swimming pool equipment and supplies. With over 80 years of experience, the company has been at the forefront of innovation in the swimming pool industry.Pipeline - Intercept Pharmaceuticals Home > Our Research > Pipeline Our Pipeline Our portfolio is based on novel scientific targets with the potential for therapeutic application …MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Intercept Pharmaceuticals Pharmaceutical Manufacturing Morristown, New Jersey 56,784 followers Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. What is PBC? Primary Biliary Cholangitis (PBC) is a progressive autoimmune disease that damages the bile ducts in the liver. PBC is a leading cause of liver transplant for women. Learn more Ally, living with PBC Patient Resources We are committed to helping patients access disease education, treatment support and financial options. Read moreIntercept Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share data) Three Months Ended March 31, 2023 2022 Revenue: Product revenue, net $ 67,958 $ 59,146 Total revenue 67,958 59,146 Operating expenses: Cost of sales 222 223Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.Follow. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitisJun 23, 2023 · MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis (NASH)-related investment. Jun 22, 2023 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC ... FIRST SUPPLEMENTAL INDENTURE dated as of August 17, 2021 (this “Supplemental Indenture”) between INTERCEPT PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Issuer,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (in such capacity, the “Trustee,” as more fully set forth in Section 1.01) and ...Dec 20, 2021 · Follow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...THIS INDENTURE, dated as of August 17, 2021 between Intercept Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and U.S. Bank National Association, a national banking association organized and existing under the laws of the United States (the “Trustee”), WITNESSETH: WHEREAS, the Issuer may from time to time duly authorize …Intercept pharmaceuticals inc

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q4 2022 Results Conference Call March 2, 2023 8:30 AM ET. Company Participants. Nareg Sagherian - Executive Director, Investor Relations.. Intercept pharmaceuticals inc

intercept pharmaceuticals inc

What is PBC? Primary Biliary Cholangitis (PBC) is a progressive autoimmune disease that damages the bile ducts in the liver. PBC is a leading cause of liver transplant for women. Learn more Ally, living with PBC Patient Resources We are committed to helping patients access disease education, treatment support and financial options. Read moreThe latest closing stock price for Intercept Pharmaceuticals, Inc. on November 07, 2023 is 19.00. The all-time high Intercept Pharmaceuticals, Inc. closing stock price was 462.26 on March 14, 2014. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Historical daily share price chart and data ...NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has ...FIRST SUPPLEMENTAL INDENTURE dated as of August 17, 2021 (this “Supplemental Indenture”) between INTERCEPT PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Issuer,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (in such capacity, …Morristown, New Jersey, UNITED STATES. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development ...Intercept Pharmaceuticals Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ICPT stock stock was $22.5, which predicted an increase of 18.42%. The lowest target was $14 and the highest was $54. On average, analysts rated ICPT stock stock as a hold.Intercept Pharmaceuticals, Inc. November 8, 2023 at 6:13 AM · 11 min read. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ...Shingles is a condition that you can develop if you’ve had chickenpox before. In recent years, pharmaceutical companies have formulated vaccines for shingles that can help you avoid coming down with this painful rash.Follow. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Medical Information. If you are a healthcare professional and have a medical inquiry, visit our Medical Information website. Learn more >. US-NP-N/A-0137. We are INTERCEPT. Our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases.Contact Us For more information call: (844) 782–4278 Corporate Headquarters 305 Madison AvenueMorristown, NJ 07960 T: (646) 747–1000 San Diego Office 3636 Nobel Drive, Suite 475,San Diego, CA 92122 T: 858-652-6800 Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Our Pipeline. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases, with a focus on those with high unmet need. We are leveraging our decades of research and background in bile acids and FXR agonism to expand our pipeline to deliver effective treatments for the growing ... To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...Dec 31, 2022 · MORRISTOWN, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2022. Nareg Sagherian, Executive Director, Global Investor Relations. [email protected]. For media: Karen Preble, Executive Director, Global Corporate Communications. media@interceptpharma ...MORRISTOWN, N.J. , July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by AlFollow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Farnesoid X Receptor Research is shedding light on the complex and powerful connection between bile acid and the farnesoid X receptor (FXR). Understand the metabolic effects of FXR. Learn more Our Pipeline Intercept is expanding its pipeline to evaluate new indications for liver diseases with limited therapeutic options. Take a look at the direction we … Continued The Discovery and Development of Natural Products for Cancer Interception and Prevention Program (DDNP-CIP) supports the discovery and development of new natural products that are safe, non-toxic, and efficacious for cancer interception and...Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC ...MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ...Farnesoid X Receptor Research is shedding light on the complex and powerful connection between bile acid and the farnesoid X receptor (FXR). Understand the metabolic effects of FXR. Learn more Our Pipeline Intercept is expanding its pipeline to evaluate new indications for liver diseases with limited therapeutic options. Take a look at the direction we … Continued Our Pipeline. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases, with a focus on those with high unmet need. We are leveraging our decades of research and background in bile acids and FXR agonism to expand our pipeline to deliver effective treatments for the growing ...Hayward Pool Products Inc. is a leading manufacturer and distributor of swimming pool equipment and supplies. With over 80 years of experience, the company has been at the forefront of innovation in the swimming pool industry.Intercept Pharmaceuticals Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ICPT stock stock was $22.5, which predicted an increase of 18.42%. The lowest target was $14 and the highest was $54. On average, analysts rated ICPT stock stock as a hold.MORRISTOWN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...Cash on Hand. Long Term Debt. Total Liabilities. Share Holder Equity. Intercept Pharmaceuticals, Inc. total assets from 2013 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet. Intercept Pharmaceuticals, Inc. Annual Total Assets. (Millions of US $)Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC ...BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ...May 26, 2021 · NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has ... Learn more about ongoing Intercept-sponsored clinical trials below. Primary biliary cholangitis (PBC) Intercept has two ongoing Phase 2 studies, 747-213 and 747-214, that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. Study 747-213 is for patients outside of the United States. Study 747-214 is for patients … ContinuedSelected Fourth Quarter and Full Year 2022 Financial Results. Intercept recognized $77.2 million in U.S. net sales in the fourth quarter 2022 as compared to $68.7 million in U.S. net sales in the ...MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug ...May 16, 2023 · MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ... The Investor Relations website contains information about Intercept Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. MORRISTOWN, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended June 30, 2022.Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced its financial results for the quarter ended on June 30, 2023.Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”).EPS. Shares Outstanding. Intercept Pharmaceuticals, Inc. gross profit from 2013 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. Intercept Pharmaceuticals, Inc. Annual Gross Profit. (Millions of US $) 2022 ...MORRISTOWN, N.J. , July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results. Read More.NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has ...Y = mx + b is the equation for a straight line. “B” is the point value of where the line intercepts the y axis, called the y intercept. “M” is the value of the slope of the line. “X” is the value where the line intercepts the x axis.Bologna, Italy– October 11, 2023 — Alfasigma S.p.A. (“Alfasigma”) today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation (“Purchaser”), has commenced a cash tender offer to purchase all of the outstanding shares of common stock, par value USD $0.001 per share, of Intercept …Intercept Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share data) Three Months Ended March 31, 2023 2022 Revenue: Product revenue, net $ 67,958 $ 59,146 Total revenue 67,958 59,146 Operating expenses: Cost of sales 222 223Cash on Hand. Long Term Debt. Total Liabilities. Share Holder Equity. Intercept Pharmaceuticals, Inc. total assets from 2013 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet. Intercept Pharmaceuticals, Inc. Annual Total Assets. (Millions of US $)Farnesoid X Receptor Research is shedding light on the complex and powerful connection between bile acid and the farnesoid X receptor (FXR). Understand the metabolic effects of FXR. Learn more Our Pipeline Intercept is expanding its pipeline to evaluate new indications for liver diseases with limited therapeutic options. Take a look at the direction we … Continued Alfasigma (NASDAQ: ICPT) has completed the tender offer to purchase all outstanding shares of Intercept Pharmaceuticals, Inc. at a price of USD 19.00 per share. 31,158,412 shares, representing approximately 74.5% of Intercept’s outstanding shares, were tendered and not withdrawn. Alfasigma expects to complete the acquisition on …Intercept Pharmaceuticals, Inc., et al., Case No. 23-cv-09052 (which we refer to as the “O’Dell Complaint”). On October 17, 2023, a purported stockholder of Intercept filed a lawsuit in the United States District Court for the Southern District of New York against Intercept and its directors, captioned Dickerson v.MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at …১৯ আগ, ২০২২ ... Intercept Pharmaceuticals Inc. has said it entered into a settlement agreement with Dr. Reddy's Laboratories resolving the previously ...MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug ...Intercept Pharmaceuticals Inc.: Intercept is a biopharmaceutical company that manufactures drugs to treat non-viral liver disease. BioNTech SE: ...The Investor Relations website contains information about Intercept Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis18.89%. $10.02M. Gilead Sciences Inc. 0.36%. $97.68B. ICPT | Complete Intercept Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial ...About us We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver...MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis (NASH)-related investment.Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ... Prescription medications are a vital element of healthcare for many people in the United States. While it’s not completely clear how pharmaceutical companies determine pricing for many drugs, some of the most expensive medications and treat...Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q4 2022 Results Conference Call March 2, 2023 8:30 AM ET. Company Participants. Nareg Sagherian - Executive Director, Investor Relations.MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …Selected Fourth Quarter and Full Year 2022 Financial Results. Intercept recognized $77.2 million in U.S. net sales in the fourth quarter 2022 as compared to $68.7 million in U.S. net sales in the ...Intercept Pharmaceuticals (NASDAQ:ICPT) is a biopharmaceutical company focused on developing and marketing innovative treatments for progressive liver diseases that are not caused by viruses.Jan 19, 2023 · MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... Nareg Sagherian, Executive Director, Global Investor Relations. [email protected]. For media: Karen Preble, Executive Director, Global Corporate Communications. media@interceptpharma ...MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Intercept Pharmaceuticals, Inc., Mark Pruzanski and Sandip S. Kapadia was filed in the United States District Court for the Southern District of New York, naming us and certain of our officers as defendants. This lawsuit was filed by a stockholder who claims to be suing on behalf of anyone who purchased or otherwise acquired our securities ...Jan 19, 2023 · MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug ... Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to …Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Prior to ...Intercept Pharmaceuticals, Inc. June 22, 2023 at 5:45 PM · 3 min read Company to discontinue all NASH-related investment and restructure the Company’s operations to strengthen its focus on rare ...MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel .... Best computers for trading